Pure Bioscience (PURE) AI Stock Analysis

• Market Cap: $5.88M
• Dividend Yield: N/A
• Average Volume (3M): 53.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.20
• Revenue Growth: 31.00%
• EPS Growth: 34.24%
• Country: US
• Employees: 11
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 111,886,480
• 10 Day Avg. Volume: 24,352
• 30 Day Avg. Volume: 53,720
• PEG Ratio: 0.15
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00456
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 2.03
• Enterprise Value/Revenue: 5.07
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: -6.49
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $0.05 ▲(4.00% Upside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is primarily held back by weak fundamentals: ongoing losses, continued cash burn, and a stressed balance sheet with negative equity and meaningful debt. Technicals are modestly better in the near term but still weak over longer timeframes, while valuation is constrained by negative earnings and no indicated dividend support. Corporate actions add financing flexibility but also raise dilution considerations.

Positive Factors

Consistent Revenue Growth

TTM revenue growth of 6.9% indicates persistent demand for the company’s SDC-based disinfectants across commercial and institutional channels. Sustainable top-line expansion improves the company’s ability to scale operations, spread fixed costs, and supports longer-term investment in product distribution and commercialization.

High Gross Margin Profile

A roughly 58% gross margin reflects strong unit economics for Pure Bioscience’s antimicrobial products, implying durable product-level profitability if production and procurement remain stable. High gross margins provide room to cover SG&A and R&D, making path to operating leverage more achievable if revenue keeps growing.

Expanded Capital-Structure Flexibility

Shareholder approval to raise authorized common stock gives management structural flexibility to raise equity, grant compensation, or pursue strategic transactions to extend runway. This legally enables future financing or M&A options that can be critical to support operations and scale without changing the core business.

Negative Factors

Negative Stockholders' Equity

Negative shareholders’ equity signals a deteriorated capital base and materially limits financial flexibility. Over time this raises refinancing and going-concern risks, can increase borrowing costs, and may constrain the company’s ability to secure vendor terms or strategic partnerships without dilutive or costly recapitalization.

Persistent Cash Burn

Consistent negative operating and free cash flow means the business relies on external capital to fund operations and growth. Ongoing cash burn increases the probability of future equity or debt raises, which can dilute shareholders or add leverage, and constrains reinvestment into sales, marketing, and R&D needed for durable expansion.

Structural Unprofitability

Deeply negative operating results indicate gross profits are insufficient to cover operating costs. Unless operating expenses are reduced or revenue accelerates materially, the structural loss profile will persist, impairing the company’s ability to generate internally funded growth and increasing dependence on external financing.

Pure Bioscience Business Overview & Revenue Model

Company Description

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

How the Company Makes Money

Pure Bioscience generates revenue through the sale of its proprietary antimicrobial solutions, primarily its Silver Dihydrogen Citrate (SDC) technology. The company targets multiple industries, such as food processing, healthcare, and consumer goods, where there is a high demand for effective and safe antimicrobial agents. Key revenue streams include direct sales to end-users, partnerships with distributors and manufacturers who incorporate SDC into their products, and licensing agreements where third parties pay for the right to use SDC technology in their own offerings. Significant partnerships with companies in the food safety and healthcare sectors bolster its earnings by expanding its market reach and application scope.

Pure Bioscience Financial Statement Overview

Summary

Revenue is growing (TTM +6.9%) with healthy gross margin (~58%), but the company remains structurally unprofitable with deeply negative operating results. Cash flow is consistently negative (TTM operating cash flow and free cash flow both -$1.76M), and the balance sheet is the largest risk with negative stockholders’ equity and meaningful debt, reducing financial flexibility and increasing financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is up (6.9% growth) and gross margin remains healthy (~58%), indicating the product can generate solid gross profit. However, the company is still structurally unprofitable with negative operating results (EBIT/EBITDA margins both deeply negative) and a very large net loss relative to sales, showing overhead and operating costs continue to overwhelm gross profit.

Balance Sheet

The balance sheet is the key weak point: stockholders’ equity is negative in the most recent periods (TTM and 2025 annual), which materially limits financial flexibility and raises refinancing/going-concern risk. Debt remains meaningful relative to a small asset base, and the shift from positive equity in earlier years to negative equity highlights a deteriorating capital position.

Cash Flow

Cash generation is consistently negative: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both -$1.76M, and free cash flow growth is also negative, pointing to ongoing cash burn rather than improving self-funding. While cash burn is somewhat lower than prior years, the business still relies on external capital to sustain operations.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	2.35M	2.20B	1.96M	1.88M	1.85M	3.93M
Gross Profit	1.30B	1.30B	1.15M	971.00K	1.00M	2.08M
EBITDA	-1.84M	-2.10M	-3.05M	-3.83M	-3.27M	-2.14M
Net Income	-2.17M	-2.40M	-3.35M	-3.96M	-3.50M	-2.32M
Balance Sheet
Total Assets	1.19M	1.06B	818.00K	1.82M	4.48M	4.30M
Cash, Cash Equivalents and Short-Term Investments	509.00K	334.00M	349.00K	1.09M	3.39M	2.39M
Total Debt	5.68M	5.24B	2.95M	1.02M	0.00	239.00K
Total Liabilities	6.73M	6.17B	3.68M	1.55M	575.00K	970.00K
Stockholders Equity	-5.55M	-5.12B	-2.86M	272.00K	3.91M	3.33M
Cash Flow
Free Cash Flow	-1.76M	-2.02B	-2.53M	-3.31M	-2.50M	-1.69M
Operating Cash Flow	-1.76M	-2.02B	-2.53M	-3.28M	-2.42M	-1.17M
Investing Cash Flow	0.00	0.00	0.00	-33.00K	-81.00K	-521.00K
Financing Cash Flow	1.85M	2.00B	1.78M	1.01M	3.50M	239.00K

Pure Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 44.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PURE.

Pure Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UG	74 Outperform	$30.05M	15.33	17.85%	9.81%	-18.29%	-43.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TANH	56 Neutral	$5.40M	-0.05	4.57%	―	-14.59%	-135.25%
TKLF	55 Neutral	$12.41M	2.01	16.79%	―	7.75%	-21.61%
PURE	49 Neutral	$5.88M	-2.68	127.81%	―	31.00%	34.24%
MTEX	46 Neutral	$13.31M	-8.10	-19.54%	―	-9.17%	-4.64%
GROV	43 Neutral	$56.70M	-2.24	-130.15%	―	-15.42%	7.12%

Pure Bioscience Corporate Events

Pure Bioscience Shareholders Back Governance, Expand Stock Authorization

Pure Bioscience, Inc. held its Annual Meeting of Stockholders on February 17, 2026, with approximately 66% of outstanding shares represented, and shareholders elected all seven director nominees with overwhelming majorities to serve until the next annual meeting. Investors also approved, on an advisory basis, the executive compensation program and ratified Weinberg & Company, P.A. as the independent auditor for the fiscal year ending July 31, 2026, signaling broad support for current governance and leadership.

In a key capital-structure move, shareholders voted to amend the company’s Certificate of Incorporation to increase authorized common stock from 200 million to 250 million shares, a step that provides added flexibility for future financing, equity compensation, or strategic transactions. No additional items were brought to a vote, underscoring that the meeting primarily reinforced existing governance arrangements while expanding the company’s capacity to issue new equity as needed.

The most recent analyst rating on (PURE) stock is a Hold with a $0.06 price target. To see the full list of analyst forecasts on Pure Bioscience stock, see the PURE Stock Forecast page.